This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 303.5% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 23.91% and 4.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
by Zacks Equity Research
Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of -97.14% and 7.74%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases.
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
by Zacks Equity Research
INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View
by Zacks Equity Research
BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.
Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 193.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
New Strong Buy Stocks for February 13th
by Zacks Equity Research
SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
by Sundeep Ganoria
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 136.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 290% and 144.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 140.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 92.54% and 810.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
by Zacks Equity Research
Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
by Zacks Equity Research
Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.
Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength
by Zacks Equity Research
Day One Biopharmaceuticals, Inc. (DAWN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 84.6% in Day One Biopharmaceuticals, Inc. (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Biotech ETF Tops in June: 5 Stocks That Outperform
by Sweta Killa
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.